The improved survival outcomes of patients with non-small-cell lung cancer (NSCLC),
largely owing to the improved control of systemic disease provided by immune-checkpoint …

PURPOSE Lazertinib is a potent, CNS-penetrant, third-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor. This global, phase III study (LASER301) …

Introduction Nearly 60% of patients with non-small cell lung cancer (NSCLC) present with
metastatic disease, and approximately 20% have brain metastases (BrMs) at diagnosis …

Patient-derived organoids (PDOs) are valuable in predicting response to cancer therapy.
PDOs are ideal models for precision oncologists. However, their practical application in …

Introduction Lazertinib is a third-generation central nervous system–penetrant tyrosine
kinase inhibitor targeting mutant EGFR in NSCLC. Lazertinib exhibited improved efficacy …

Background Both first and second-generation EGFR-TKIs are recommended in advanced
NSCLC with common EGFR mutations. However, there are few data on the difference in …

Introduction Dacomitinib showed superior progression-free survival (PFS) and overall
survival compared to gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) …

Purpose This subgroup analysis of the Korean subset of patients in the phase 3 LASER301
trial evaluated the efficacy and safety of lazertinib versus gefitinib as first-line therapy for …

Background This study aimed to evaluate the efficacy and side effects of first-line afatinib
treatment in a real-world setting in Vietnam. Methods This retrospective study was …

Background Afatinib can be started at a dose lower than the recommended starting dose of
40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small …